Multiple Sclerosis Journal · 2019 · 69 citations · 24 references
Life SciencesImmunologyNeurologyClinical ImmunologyImmunopathologyNeuropathologyAutoantibodiesDemyelinating DiseasesDemyelinating DisordersAntibodiesDisability Status AnalysisMog Antibody DiseaseMog Antibody-associated DiseaseMyelin AntigensMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseMyelin-associated GlycoproteinPrognostic Factors Analysis
Objectives: We aim to (1) determine the frequency and distinctive features of short myelitis (SM) and longitudinally extensive transverse myelitis (LETM) in a cohort of adults with myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated myelitis and (2) determine baseline prognostic factors among MOG-Ab-positive patients whose disease started with myelitis. Material and Methods: We retrospectively analyzed clinical and paraclinical variables from a multicentric French cohort of adults with MOG-Ab-associated myelitis. At last follow-up, patients were classified into two groups according to the severity of the Expanded Disability Status Scale (EDSS) as ⩽2.5 or ⩾3.0. Results: Seventy-three patients with at least one episode of myelitis over disease course were included; among them, 28 (38.4%) presented with SM at the time of the first myelitis. Motor and sphincter involvement was less frequently observed in SM (51.9% and 48.2%, respectively) than in LETM patients (83.3% and 78.6%, respectively), p = 0.007 and p = 0.017; 61% of LETM patients displayed brain lesions compared to 28.6% in the SM group, p = 0.008, and the thoracic segment was more frequently involved in the LETM (82.2%) than in the SM group (39.3%), p < 0.001. EDSS at last follow-up was higher in LETM (median 3.0 (interquartile range: 2.0–4.0)) compared to SM patients (2.0, (1.0–3.0)), p = 0.042. Finally, a higher EDSS at onset was identified as the only independent risk factor for EDSS ⩾3.0 (odds ratio, 1.40, 95% confidence interval (CI): 1.01–1.95, p = 0.046). Conclusion: SM in MOG-Ab-associated disease is not rare. The severity at onset was the only independent factor related to the final prognosis in MOG-Ab-associated myelitis.
24
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.5K citations · Full text
Medicine, Neurology, Neuroscience +15
Sven Jarius, Klemens Ruprecht, Ingo Kleiter et al. · Journal of Neuroinflammation · 2016 · 891 citations · Full text
Medicine, Neurology, Neuroscience +15
Clinical presentation and prognosis in MOG-antibody disease: a UK study
Maciej Juryńczyk, Silvia Messina, Mark Woodhall et al. · Brain · 2017 · 730 citations · Full text
Life Sciences, Immunology, Neurology +17